Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052649 | 0.95 | MAP2K1 (0.49) | MAP2K1MAP2K2MAPK1MAP2K5BRAF | |
| SCHEMBL4861446 | 0.91 | MAP2K1 (0.59) | MAP2K1MAP2K2MAPK1MAP2K5BRAF | |
| SCHEMBL4861383 | 0.91 | MAP2K1 (0.56) | MAP2K1MAP2K2MAPK1MAP2K5BRAF | |
| SCHEMBL4860879 | 0.90 | MAP2K1 (0.60) | MAP2K1MAP2K2MAPK1MAP2K5BRAF | |
| SCHEMBL4862262 | 0.90 | MAP2K1 (0.56) | MAP2K1MAP2K2MAPK1MAP2K5BRAF | |
| SCHEMBL4861013 | 0.90 | MAP2K1 (0.48) | MAP2K1MAP2K2MAPK1MAP2K5BRAF | |
| SCHEMBL4851751 | 0.89 | MAP2K1 (0.56) | MAP2K1MAP2K2MAPK1MAP2K5BRAF | |
| SCHEMBL4858224 | 0.89 | MEN1 (0.50) | MAP2K1MAP2K2MAPK1MAP2K5BRAF | |
| SCHEMBL4861437 | 0.89 | MAP2K1 (0.53) | MAP2K1MAP2K2MAPK1MAP2K5BRAF | |
| SCHEMBL4861059 | 0.88 | MAP2K1 (0.55) | MAP2K1MAP2K2MAPK1MAP2K5BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| CN-1219753-C | Oxygenated esters of 4-iodophenylamino phenoxy hydroxamic acid | WARNER LAMBERT CO (US) | 2005-09-21 | — | — | CN | disclosed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885MAPK1 4734/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MAP2K2 4025/4885MAPK1 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.